The most notable clinical success using ErbB-mAbs leading to FDA approval was accomplished using trastuzumab (Herceptin, 1998, breast cancer targeting HER2) and cetuximab (Erbitux, targeting HER1 or EGFR) which significantly prolonged head and neck squamous cell carcinoma (HNSCC) patient survival (from 29.3 to 49 months) when combined with chemo- (Cisplatin or carboplatin and 5-Fluorouracil) and radiotherapy [58, 59]. This evidence concerns the gene ERBB2 and breast carcinoma.